Young women are at increased risk for developing more aggressive subtypes of breast cancer. Although previous studies have shown a higher risk of breast cancer recurrence and death among young women with early-stage breast cancer, they have not adequately addressed the role of tumor subtype in outcomes.
INTRODUCTION
Although approximately 6% to 7% of women diagnosed with breast cancer each year in the United States are 40 years of age or younger, breast cancer is the leading cause of cancerrelated deaths in this population. Moreover, the 5-year relative survival rate for women diagnosed with breast cancer before age 40 years is 85%, compared with 90% among women diagnosed at age 40 or older. 1 Prior research has revealed that young age is a risk factor for breast cancer recurrence and death, despite the more intensive treatment that young women conventionally receive compared with older women.
2 This seeming contradiction may be related to differences in tumor biology and/or host differences between younger and older women.
Breast cancer is phenotypically diverse in prognosis and response to treatment. This diversity has resulted in the delineation of a molecular taxonomy of the disease. In 2000, gene expression profiling in 65 breast cancer and normal breast samples identified a set of 496 intrinsic genes that clustered breast tumor profiles into four groups: basal-like, ERBB2 positive (human epidermal growth factor receptor 2 [HER2] positive), normal-breast-like, and luminal epithelial/estrogen receptor (ER) positive. 3 More recent work integrating clinicopathologic and gene expression data has revealed that receptor phenotype and grade can be used as surrogates for the main molecular subtypes. 4 Numerous studies, including expression profiling, array comparative genomic hybridization, and proteomic analyses, have confirmed the distinct molecular subtypes of breast cancer, which in turn are associated with differing risks of early disease recurrence, sites of metastases, response to therapy, and overall survival. [5] [6] [7] [8] The identification of molecular subtypes has aided in the development and validation of treatments for breast cancer that have improved prognosis for particular subgroups of patients. In particular, there has been great success with endocrine therapy for estrogen-responsive tumors. 9, 10 Numerous studies have documented that young women are more likely to develop more aggressive subtypes of breast cancer with unfavorable prognostic features, as well as present with more advanced disease stage. [11] [12] [13] A majority of tumors in all age groups are hormone receptor positive and ERBB2 (HER2) negative, but compared with tumors in older women, those in young women are more likely to be high grade, be hormone receptor-negative, have high proliferation fraction, and exhibit lymphovascular invasion. Accumulating evidence suggests that young women are more likely to develop more aggressive tumor molecular subtypes, including a greater proportion of triple-negative or ERBB2 overexpressing tumors.
14- 16 The few studies to date that have evaluated the effect of age on disease outcome when considering modern tumor subtypes have suggested that the effect of age on outcomes may vary by tumor phenotype. [17] [18] [19] [20] [21] However, studies have been limited by small sample size and tumor subtyping availability, as well as a lack of robust outcome data, particularly regarding mortality. In an effort to assess the role of tumor subtype on outcome disparities by age, we evaluated the effect of age on breast cancer mortality using a longitudinal cohort study, the National Comprehensive Cancer Network (NCCN) Breast Cancer Outcomes Database Project. The NCCN Database is one of the few large data sets to have collected tumor characteristics, including receptor status, such as ER, progesterone receptor (PR), and HER2, and to have tracked disease recurrence and survival.
METHODS

Participants
The Each center is an academic comprehensive cancer center at which the majority of surgical and medical oncologists treating breast cancer devote most or all of their clinical effort to breast cancer care. The institutional review board at each center approved the study, data collection process, data transmission methods, and data storage protocols. Patients presenting for second opinions and those receiving no primary therapy at the NCCN institution were excluded from the database.
We identified 20,025 stage I, II, and III patients who presented with a new diagnosis of unilateral breast cancer and received primary therapy at one of the NCCN institutions between January 1, 2000, and December 31, 2007 (Fig 1) . We excluded those who had a previous cancer diagnosis (n = 1,572), as well as those missing ER, PR, or HER2 status (n = 854) and those with no follow-up information (n = 24). Our final sample included 17,575 women.
Data Sources
The NCCN Breast Cancer Outcomes Database Project collected data prospectively on sociodemographic, tumor, and treatment characteristics, as well as outcomes on newly diagnosed patients with breast cancer at participating NCCN institutions from 1997 to 2012. The database contained tumor information on size, nodal status, histologic grade, hormone receptor status, and HER2 status, as abstracted from pathology reports, and detailed treatment information on surgical, chemotherapy, immunotherapy, and endocrine therapy, as abstracted from medical records. 22, 23 HER2 status by immunohistochemistry was added to the NCCN data as a routinely collected data element in 1999; HER2 status by fluorescent in situ hybridization was added in 2001. In addition, patient-reported sociodemographic elements were collected via survey on first presentation at most centers. The survey collected information on race/ethnicity, employment status at diagnosis, educational status at presentation to the NCCN center (defined as the highest level of education completed), and menopausal status. Vital status and cause of death were abstracted by annual chart review through 2012, with a secondary search of the Social Security Death Index and the National Death Index, current as of December 31, 2009. This was then coded in the database using International Classification of Diseases (9th revision, clinical modification) codes. Rigorous data quality assurance processes as previously documented were in place for the study.
23,24
Variable Definitions
For HER2 status classification, fluorescent in situ hybridization result was used, if available. If only immunohistochemistry was available, 3+, high positive, or positive/not otherwise specified were considered HER2 positive, whereas 2+, 1+, and 0 or negative were considered HER2 negative. For molecular subtype classification, patients were classified into four subtype groups: luminal A (ER positive and/or PR positive, HER2 negative, and low/intermediate grade); luminal B (ER positive and/or PR positive and HER2 positive; or ER positive and/or PR positive and HER2 negative and high grade); HER2 (ER negative, PR negative, and HER2 positive); and triple negative (ER negative, PR negative, and HER2 negative). 
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Analyses
We summarized patient and clinical characteristics at the time of first presentation to the NCCN institution, stratified by age at diagnosis (# 40, 41 to 50, 51 to 60, 61 to 70, and . 70 years). P values in Table 1 were obtained from x 2 tests. We used the 51-to 60-year-old age group as the reference category because it had the greatest number of people and allowed us to examine the association among both younger and older populations. Followup was defined as time in years from breast cancer diagnosis to date of death or last date of NCCN follow-up. Breast cancer-specific survival was determined by identifying breast cancer as the cause of death using International Classification of Disease codes 174 and 174.9. We used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% CIs for the relationship between age group and breast cancerspecific survival. Visual assessment of Kaplan-Meier curves suggested no violation of the proportional hazards assumption. We assessed the association overall and stratified by breast cancer subtype.
We conducted multivariable analyses with stepwise adjustment, beginning with sociodemographic characteristics, including race/ethnicity (categorical), insurance type (Medicare, Medicaid, managed care, indemnity, or other/unknown/uninsured), educational attainment (high school or less, some college, college graduate, graduate school), employment status (employed or student; homemaker or retired; or unable to work, unemployed, or other), and NCCN center. Next, we also accounted for tumor characteristics and treatment: stage at diagnosis, tumor grade (high-grade or low/intermediate), year of diagnosis (continuous), receipt of adjuvant chemotherapy (yes/no), endocrine therapy (yes/no), or trastuzumab (yes/no). We then conducted separate analyses within each breast cancer subtype (luminal A, luminal B, HER2, and triple-negative). For covariates that had missing data, we included a missing category that was included in the analysis.
All statistical tests were two-sided, and P values , .05 were considered statistically significant. Analyses were conducted using SAS (version 9.2, SAS Institute, Cary, NC).
RESULTS
Patient and tumor characteristics and treatments by age at diagnosis are presented in Table 1 . Among 17,575 women with breast cancer eligible for analysis, 1,916 were # 40 years of age at diagnosis, with a mean age of 35 years; the mean age of women . 40 years of age was 57 years. Median follow-up time was 6.42 years overall. This ranged from 6.21 years for HER2-type tumors to 6.45 years for luminal A tumors. Compared with older women, younger women were more likely to be nonwhite, premenopausal, more educated, and employed or in school (P , .001). Younger women also were more likely to have higher-stage and higher-grade disease, and their tumors were more likely to be of luminal B, triplenegative, or HER2 subtype (P , .001). In addition, younger women were more likely to receive chemotherapy compared with the older group (P , .001).
Relationship Between Younger Age and Breast Cancer Mortality
In a multivariable model controlling for demographic characteristics, we found that women # 40 years old were 90% more likely to die of breast cancer than were women ages 51 to 60 years at diagnosis (HR, 1.9; 95% CI, 1.6 to 2.3; Table 2 ). Additional adjustment controlling for treatment, stage at diagnosis, tumor grade, and year of diagnosis attenuated the association, and women # 40 years old were 50% more likely to die of their breast cancer than were women ages 51 to 60 (HR, 1.5; 95% CI, 1.3 to 1.8). After adjusting for tumor molecular subtype and detection method (symptomatic or screen), the association was further attenuated; however, women # 40 years old remained 30% more likely to die of their breast cancer than were women ages 51 to 60 years (HR, 1.3; 95% CI, 1.1 to 1.5). In fully adjusted models, there was no difference in survival among women ages 41 to 50 years (HR, 0.9; 95% CI, 0.8 to 1.1), 61 to 70 years (HR, 0.8; 95% CI, 0.7 to 1.0), or .70 years (HR, 1.0; 95% CI, 0.7 to 1.4) compared with women ages 51 to 60 years.
Stratification by Tumor Subtype
We examined the association between age group and breast cancer mortality, stratifying by tumor subtype (Table 3 ). Among women with luminal A disease (n = 7,738), when controlling for patient, disease, and treatment factors, women # 40 years of age at diagnosis were more than twice as likely to die of breast cancer compared with women ages 51 to 60 years (HR, 2.1; 95% CI, 1.4 to 3.2). In women with luminal B disease, the younger women also had greater breast cancer mortality (HR, 1.4; 95% CI, 1.1 to 1.9), and for women with triple-negative disease, young age was associated with borderline increased risk (HR, 1.4; 95% CI, 1.0 to 1.8). In contrast, among women with HER2-positive disease, young age was not significantly associated with breast cancerspecific mortality when controlling for other prognostic factors (HR, 1.2; 95% CI, 0.8 to 1.9). Furthermore, in subset analysis of the luminal B group (data not shown), the increased risk demonstrated seemed to be largely due to the HER2-negative subgroup. When we controlled for detection method, these relationships were attenuated, and poor prognostic effect of young age on mortality was seen primarily in women with luminal A disease.
DISCUSSION
Young age at diagnosis has long been considered a poor prognostic factor, because young women, on average, have an increased risk of disease recurrence and decreased survival. 12, 13, 25 In recent years, however, with improved understanding of tumor biology, this assertion has been challenged with increased recognition of the prognostic and predictive role of tumor subtype and awareness that young women are more likely to develop more aggressive phenotypes.
14, 16, 26, 27 Our study expands on this work to demonstrate that in a large national sample where control of tumor subtype is possible, young age is a prognostic factor in certain breast cancer subtypes, but not others.
In women with HER2-positive disease, prior analysis in a clinical trial population receiving modern therapy demonstrated that young age was neither prognostic nor predictive of short-term outcome among women treated with chemotherapy, whether followed by trastuzumab or not. 18 In the setting of triple-negative breast cancer, the risk of recurrence also seems to be similar in older women compared with younger women when controlling for other conventional prognostic factors. 27, 28 In this report, we found that in women with HER2-type or triple-negative breast cancer, there was no clear increased risk of breast cancer mortality among women # 40 years of age compared with women 51 to 60 years of age. Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor. *P value from x 2 test. †ER positive and/or PR positive, HER2 negative/low grade. ‡ER positive and/or PR positive, HER2 positive; or ER positive and/or PR positive, HER2 negative/high grade. §ER negative, PR negative, and HER2 positive. kER negative, PR negative, and HER2 negative.
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This growing body of evidence suggests that in these two more aggressive phenotypes, outcomes are similar regardless of age at diagnosis, although the incidence of these more aggressive tumors in young women is higher. The finding that among women with luminal breast cancer, age seems to remain an independent prognostic factor has been observed previously and merits further consideration. 12, 27 Luminal A and B subtypes are characterized by the expression of hormone receptors and potential sensitivity to endocrine manipulations, and benefit from adjuvant endocrine therapy or the chemoendocrine effect of chemotherapy in premenopausal women. There are several potential mechanisms by which young women may not get the same benefits as older women. In older series, tamoxifen was not commonly administered to young women; therefore, they would not have received the potential benefits in terms of risk reduction. Chemotherapy-related amenorrhea, which is associated with improved outcomes, particularly in women with endocrine sensitive tumors, is less likely to occur in younger women. 29, 30 Young age also is a predictor of decreased adherence with adjuvant endocrine therapy, associated with increased mortality. [31] [32] [33] [34] [35] Hershman et al 32 reported that women # 40 years were 40% more likely to be nonadherent than were those ages 50 to 65 years (P , .001). Similarly, Huiart et al 34 found that 40% of women with early breast cancer with a mean age younger than 40 years had discontinued tamoxifen after 3 years of treatment. Adherence in this population is a critical issue that needs to be addressed, given the demonstrated efficacy of endocrine therapy in reducing the risk of recurrence and death among women with luminal disease. Uptake in clinical practice of recent findings demonstrating incremental benefits from combined ovarian suppression and either tamoxifen or an aromatase inhibitor in young women may help to reduce disparities by age among those with higher-risk luminal tumors in particular. 36, 37 It also is possible that tumors arising in young women have different biologic characteristics than do those that arise in older women, even within tumor subtypes. Younger women are more likely to harbor a BRCA1, BRCA2, or other cancer-related genetic-associated tumor.
38 Yet, it is not clear whether this factor negatively affects survival, particularly if women are given chemotherapy. 39, 40 Tumors in young women have lower mRNA expression of ER-alpha, ER-beta, and PR, with higher HER2 and epidermal growth factor receptor expression. 41 Although these differences diminish when considering differences in molecular subtype distribution by age, there may be residual age-related differences in gene expression beyond subtype. Azim et al 16 demonstrated that tumors in young women were enriched with phosphatidylinositol 3-kinase, extracellular signalrelated kinase-related genes, and genes for mammary stem cells, luminal progenitor cells, c-kit, and receptor activator of nuclear factor kappa-B ligand, while accounting for subtype distribution. Lastly, younger women are more likely to have pregnancy-associated breast cancer (disease diagnosed in the 1 to 5 years after a pregnancy), which is correlated with poor prognosis and enriched tumor expression of genes in several cancer pathways.
19, 42 Future research is warranted to determine whether these biologic differences in tumors of young women contribute to subtype-specific survival differences.
To our knowledge, this study was the largest comprehensive evaluation to date to assess the relationship between patient age and breast cancer mortality while controlling for modern tumor subtyping, including HER2 status. A major strength of the study was the availability of detailed patient, tumor, and treatment information in a large, diverse, multicenter observational cohort of women with breast cancer. However, our results should be considered in light of the possible limitations of this research. The NCCN database enrolled patients only from large comprehensive cancer centers and is not population based; therefore, the experiences of women in this study may not be generalizable to all women with breast cancer. It is possible that younger women with more aggressive cancers preferentially choose to come to these centers and therefore may bias these results. We ascertained tumor characteristics and subtypes from medical records, thus using hormone receptor status and grade from medical records as surrogates for determination of molecular subtype. However, at least for ER status, pathology reports are a demonstrated reasonable alternative to central laboratory testing. 43 Lastly, because we lacked information on cytokeratin 5/6 and epidermal growth factor receptor, we could not precisely identify basal-like subtypes. Nevertheless, this study supports the growing evidence that the relationship between age at diagnosis and breast cancerspecific survival varies by tumor subtype, which has implications for both treatment decisions and future research directions. Young age does not seem to be an independent predictor of outcome when controlling for other factors in women with triple-negative and HER2 subtype tumors. However, in women with luminal disease, younger age does have a substantial prognostic role, which may reflect inadequate therapy, including lower treatment efficacy and less therapeutic adherence and persistence, as well as residual differences in tumor biology. In a previous study that was based on this data set, we demonstrated similar persistent disparities among black women with luminal tumors, suggesting that targeted interventions for young and black women with these tumors is an important step toward reducing age and race-related disparities in breast cancer. 44 Research on improving outcomes should focus on disease, treatment, access, and behavioral issues in an effort to reduce mortality. The effect of age on survival of women with early breast cancer seems to vary by breast cancer subtype, and age seems to be particularly prognostic in women with luminal A and luminal B, HER2-negative breast cancer. Further research to elucidate differences in breast cancer biology and efficacy of therapy among young women with luminal breast cancer by age may identify targets to improve outcomes in this higher-risk population.
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